White & Case LLP is advising leading global investment firm EQT, through EQT VIII and Karo Intressenter AB, on the public cash offer to the shareholders of Karo Pharma AB (Karo Pharma) to acquire all shares in Karo Pharma.
The shareholders are being offered SEK 36.90 in cash per share in Karo Pharma. The total offer, based on all outstanding shares, amounts to SEK 5.973 billion (US$654 million). The transaction is subject to a number of customary closing conditions and is expected to complete before the end of 2018.
Founded in 1994, EQT is a leading global investment firm with offices in 14 countries across Europe, North America and Asia. It has raised €50 billion from around 600 global institutional investors across 27 funds.
Founded in 1987 and listed on Nasdaq Stockholm, Karo Pharma is a specialist Nordic pharmaceutical company that develops and markets products for pharmacies, as well as directly to the healthcare sector. Its product portfolio includes over-the-counter and prescription pharmaceuticals, medical devices, proprietary and under license.
White & Case advised EQT with a team including Jan Jensen (Picture), Rikard Stenberg, Johan Thiman and Oscar Liljeson, counsel Peter Svanqvist and associates Patrik Erblad, David Riihonen, Erik Larsson, Rebecka Tenenbaum, Anders Westling, Petar Bojovic, Gustaf Wiklund and Björn Torsteinsrud.
Involved fees earner: Jan Jensen – White & Case; Rikard Stenberg – White & Case; Patrik Erblad – White & Case; David Riihonen – White & Case; Erik Larsson – White & Case; Rebecka Tenenbaum – White & Case; Anders Westling – White & Case; Johan Thiman – White & Case; Gustaf Wiklund – White & Case; Björn Torsteinsrud – White & Case; Oscar Liljeson – White & Case; Peter Svanqvist – White & Case; Petar Bojovic – White & Case;
Law Firms: White & Case;
Clients: EQT Partners;